ZEAL — Zealand Pharma A/S Share Price
Last trade - 00:00- DKK30.00bn
- DKK22.17bn
- DKK62.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 158.45 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.48 | ||
| Price to Tang. Book | 3.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 478.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.98% | ||
| Return on Equity | -21.13% | ||
| Operating Margin | -2029.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 192 | 108.55 | 103.99 | 342.79 | 62.69 | 4,041.57 | 2,500.18 | 8.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Directors
- Alf Nicklasson CHM (66)
- Emmanuel Dulac PRE (52)
- Kirsten Drejer VCH (65)
- Matthew Dallas CFO (46)
- Adam Steensberg EVP (47)
- Marino Garcia SVP (55)
- Ivan Moeller SVP (49)
- Frank Sanders SVP
- Frederik Beck DRC (54)
- Iben Gjelstrup DRC (44)
- Alain Munoz DRC (73)
- Anneline Nansen DRC
- Jens Stenvang DRC (67)
- Jeffrey Berkowitz IND (55)
- Bernadette Connaughton IND (63)
- Leonard Kruimer IND (63)
- Michael Owen IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 1997
- Public Since
- November 1st, 2010
- No. of Shareholders
- 49,575
- No. of Employees
- 335
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 70,677,795
- Address
- Sydmarken 11, SOEBORG, 2860
- Web
- https://www.zealandpharma.com/
- Phone
- +45 null88773600
- Contact
- Anna Krassowska
- Auditors
- Ernst & Young Godkendt Revisionspartnerselskab
Latest News for ZEAL
Upcoming Events for ZEAL
Q1 2025 Zealand Pharma A/S Earnings Release
Q2 2025 Zealand Pharma A/S Earnings Release
Similar to ZEAL
Genmab A/S
OMX Nordic Exchange - Copenhagen
Gubra A/S
OMX Nordic Exchange - Copenhagen
Strategic Partners A/S
OMX Nordic Exchange - Copenhagen
ViroGates A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 24:14 UTC, shares in Zealand Pharma A/S are trading at DKK424.50. This share price information is delayed by 15 minutes.
Shares in Zealand Pharma A/S last closed at DKK424.50 and the price had moved by -29.83% over the past 365 days. In terms of relative price strength the Zealand Pharma A/S share price has underperformed the FTSE Global All Cap Index by -31.07% over the past year.
The overall consensus recommendation for Zealand Pharma A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZealand Pharma A/S does not currently pay a dividend.
Zealand Pharma A/S does not currently pay a dividend.
Zealand Pharma A/S does not currently pay a dividend.
To buy shares in Zealand Pharma A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK424.50, shares in Zealand Pharma A/S had a market capitalisation of DKK30.00bn.
Here are the trading details for Zealand Pharma A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: ZEAL
Based on an overall assessment of its quality, value and momentum Zealand Pharma A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zealand Pharma A/S is DKK969.23. That is 128.32% above the last closing price of DKK424.50.
Analysts covering Zealand Pharma A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK6.58 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zealand Pharma A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -45.84%.
As of the last closing price of DKK424.50, shares in Zealand Pharma A/S were trading -44.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zealand Pharma A/S PE ratio based on its reported earnings over the past 12 months is 158.45. The shares last closed at DKK424.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zealand Pharma A/S' management team is headed by:
- Alf Nicklasson - CHM
- Emmanuel Dulac - PRE
- Kirsten Drejer - VCH
- Matthew Dallas - CFO
- Adam Steensberg - EVP
- Marino Garcia - SVP
- Ivan Moeller - SVP
- Frank Sanders - SVP
- Frederik Beck - DRC
- Iben Gjelstrup - DRC
- Alain Munoz - DRC
- Anneline Nansen - DRC
- Jens Stenvang - DRC
- Jeffrey Berkowitz - IND
- Bernadette Connaughton - IND
- Leonard Kruimer - IND
- Michael Owen - IND